Exchange: NASDAQ·Updated 08:28 AM EDT
News
all
press releases
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -150.00% and +1.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?
Kyntra Bio (KYNB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
Zacks
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday
Cytek Biosciences (NASDAQ:CTKB) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cytek-biosciences-inc-stock...
MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Recommendation of "Hold" from Analysts
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have been assigned an average rating of "Hold" from the six ratings firms that are covering the stock, Marketbeat.com reports. Two...
MarketBeat
249,812 Shares in Cytek Biosciences, Inc. $CTKB Purchased by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 249,812 shares of the company's stock, valued at a...
MarketBeat
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB
Tudor Investment Corp ET AL purchased a new stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to the company in its most recent 13F filing...
MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) have received a consensus recommendation of "Hold" from the six analysts that are presently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have given a hold rati...
MarketBeat

Advertisement|Remove ads.